Status:
COMPLETED
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.
Eligibility Criteria
Inclusion
- Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.
Exclusion
- Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.
- Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.
- The subject has uncontrolled hypotension (SBP\<90mmHg).
- Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
1012 Patients enrolled
Trial Details
Trial ID
NCT01176968
Start Date
September 1 2010
End Date
October 1 2012
Last Update
December 22 2020
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
2
Walter C Mackenzie Health Sciences Centre (WCM)
Edmonton, Alberta, Canada, T6G 2B7
3
Diamond Health Care Centre (DHCC)
Vancouver, British Columbia, Canada, V5Z 1M9
4
Vancouver General Hospital - Centennial Pavilion
Vancouver, British Columbia, Canada, V5Z 1M9